The Association Between Gene Polymorphisms and Infectious Complications After Liver Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-01-31

Study Completion Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to test whether the presence of polymorphisms in genes encoding substances of the innate immune response in patients undergoing partial hepatic resection because of benign or malignant hepatobiliary disease is related to a higher incidence of infectious complications, post-resectional liver failure or mortality.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Studies on Immunopathogenesis of Liver Fibrosis

NCT04943978

Chronic Liver Disease

RECRUITING

Inflammatory and Anti-Inflammatory Gene Expressions in Liver Transplant Patients

NCT05852964

Liver Transplant; Complications Infections Gene Amplification +1 more

UNKNOWN

Cytokines and the Risk of Infection in Liver Cirrhosis

NCT00857181

Liver Cirrhosis

TERMINATED

Gene Polymorphism of IL17 and IL 23

NCT04948515

COVID-19 Respiratory Infection

COMPLETED

Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients

NCT01672164

Liver Transplant Recipients Liver Transplantation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Partial hepatic resection is a feasible and relatively safe procedure for selected patients with benign or malignant hepatobiliary disease. Liver failure after partial hepatic resection, so-called post-resectional liver failure (PLF), is a dreaded complication with high mortality rates. Patients suffering from PLF experience significantly more clinically significant infections (CSI) when compared with patients without PLF. The liver plays an important role in the body's innate immune defense. Recently, polymorphisms in genes encoding key molecules in the innate immune response (e.g. nuclear factor kappa-B) have shown to be associated with a greater risk of CSI. The presence of these polymorphisms combined with partial hepatic resection might render patients susceptible to the development of CSI, PLF and early mortality after liver resection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

liver surgery

patients with benign or malignant hepatobiliary disease requiring partial hepatic resection

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \>18 years
* benign or malignant liver disease requiring partial hepatic resection

Exclusion Criteria

* inability to give informed consent
* liver disease judged irresectable after intra-operative evaluation
* use of immunosuppressive drugs
* resection \< 1 segment
* unable to comply with follow-up

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No